Dataset Information

AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.

ABSTRACT:

Background

AKI is a common sequela of coronavirus disease 2019 (COVID-19). However, few studies have focused on AKI treated with RRT (AKI-RRT).

Methods

We conducted a multicenter cohort study of 3099 critically ill adults with COVID-19 admitted to intensive care units (ICUs) at 67 hospitals across the United States. We used multivariable logistic regression to identify patient-and hospital-level risk factors for AKI-RRT and to examine risk factors for 28-day mortality among such patients.

Results

A total of 637 of 3099 patients (20.6%) developed AKI-RRT within 14 days of ICU admission, 350 of whom (54.9%) died within 28 days of ICU admission. Patient-level risk factors for AKI-RRT included CKD, men, non-White race, hypertension, diabetes mellitus, higher body mass index, higher d-dimer, and greater severity of hypoxemia on ICU admission. Predictors of 28-day mortality in patients with AKI-RRT were older age, severe oliguria, and admission to a hospital with fewer ICU beds or one with greater regional density of COVID-19. At the end of a median follow-up of 17 days (range, 1-123 days), 403 of the 637 patients (63.3%) with AKI-RRT had died, 216 (33.9%) were discharged, and 18 (2.8%) remained hospitalized. Of the 216 patients discharged, 73 (33.8%) remained RRT dependent at discharge, and 39 (18.1%) remained RRT dependent 60 days after ICU admission.

Conclusions

AKI-RRT is common among critically ill patients with COVID-19 and is associated with a hospital mortality rate of >60%. Among those who survive to discharge, one in three still depends on RRT at discharge, and one in six remains RRT dependent 60 days after ICU admission.

SUBMITTER: Gupta S

PROVIDER: S-EPMC7894677 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.

Gupta Shruti S Coca Steven G SG Chan Lili L Melamed Michal L ML Brenner Samantha K SK Hayek Salim S SS Hayek Salim S SS Sutherland Anne A Puri Sonika S Srivastava Anand A Leonberg-Yoo Amanda A Shehata Alexandre M AM Flythe Jennifer E JE Rashidi Arash A Schenck Edward J EJ Goyal Nitender N Hedayati S Susan SS Dy Rajany R Bansal Anip A Athavale Ambarish A Nguyen H Bryant HB Vijayan Anitha A Charytan David M DM Schulze Carl E CE Joo Min J MJ Friedman Allon N AN Zhang Jingjing J Sosa Marie Anne MA Judd Eric E Velez Juan Carlos Q JCQ Mallappallil Mary M Redfern Roberta E RE Bansal Amar D AD Neyra Javier A JA Liu Kathleen D KD Renaghan Amanda D AD Christov Marta M Molnar Miklos Z MZ Sharma Shreyak S Kamal Omer O Boateng Jeffery Owusu JO Short Samuel A P SAP Admon Andrew J AJ Sise Meghan E ME Wang Wei W Parikh Chirag R CR Leaf David E DE Leaf David E DE

Journal of the American Society of Nephrology : JASN 20201016 1

<h4>Background</h4>AKI is a common sequela of coronavirus disease 2019 (COVID-19). However, few studies have focused on AKI treated with RRT (AKI-RRT).<h4>Methods</h4>We conducted a multicenter cohort study of 3099 critically ill adults with COVID-19 admitted to intensive care units (ICUs) at 67 hospitals across the United States. We used multivariable logistic regression to identify patient-and hospital-level risk factors for AKI-RRT and to examine risk factors for 28-day mortality among such p ...[more]

PMID: 33067383

Similar Datasets

Project description:BackgroundCritically ill coronavirus disease 2019 (COVID-19) patients have a high risk of acute kidney injury (AKI) that requires renal replacement therapy (RRT). A state of hypercoagulability reduces circuit life spans. To maintain circuit patency and therapeutic efficiency, an optimized anticoagulation strategy is needed. This study investigates whether alternative anticoagulation strategies for RRT during COVID-19 are superior to administration of unfractionated heparin (UFH).MethodsRetrospective cohort study on 71 critically ill COVID-19 patients (≥18 years), admitted to intensive care units at a tertiary health care facility in the southwestern part of Germany between February 26 and May 21, 2020. We collected data on the disease course, AKI, RRT, and thromboembolic events. Four different anticoagulatory regimens were administered. Anticoagulation during continuous veno-venous hemodialysis (CVVHD) was performed with UFH or citrate. Anticoagulation during sustained low-efficiency daily dialysis (SLEDD) was performed with UFH, argatroban, or low molecular weight heparin (LMWH). Primary outcome is the effect of the anticoagulation regimen on mean treatment times of RRT.ResultsIn patients receiving CVVHD, mean treatment time in the UFH group was 21.3 h (SEM: ±5.6 h), in the citrate group 45.6 h (SEM: ±2.7 h). Citrate anticoagulation significantly prolonged treatment times by 24.4 h (P = .001). In patients receiving SLEDD, mean treatment time with UFH was 8.1 h (SEM: ±1.3 h), with argatroban 8.0 h (SEM: ±0.9 h), and with LMWH 11.8 h (SEM: ±0.5 h). LMWH significantly prolonged treatment times by 3.7 h (P = .008) and 3.8 h (P = .002), respectively.ConclusionsUFH fails to prevent early clotting events in the dialysis circuit during COVID-19. For patients, who do not require effective systemic anticoagulation, regional citrate dialysis is the most effective strategy. For patients, who require effective systemic anticoagulation, the usage of LMWH results in the longest circuit life spans. The proposed anticoagulatory strategies are safe, can easily be monitored, and allow an individualized treatment.

Dataset Information

AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.

Background

Methods

Results

Conclusions

Publications

AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets